Group 1 - By the end of 2025, 93 Chinese companies successfully listed on US stock markets, with 149 companies publicly submitting listing applications, showing moderate growth compared to 69 companies in 2024 [1] - Nasdaq maintained its absolute advantage with 89 companies listed, accounting for 96% of the total, while only 4 companies chose the New York Stock Exchange [1] - The industry distribution is diverse, with technology companies like application software leading, while traditional industries such as construction and industrial sectors follow steadily, and modern service industries like pharmaceuticals and food logistics show vibrant growth, reflecting the robust momentum of China's economic transformation [1] Group 2 - Among the three main listing paths, IPO remains the mainstream route, favored for its direct financing and brand premium advantages, with 84 Chinese concept stocks completing their US listings through IPOs [1] - Smithfield (SFD) topped the list with over $500 million raised, becoming the largest IPO project of the year, followed by Bawang Tea (CHA) with $411 million, and Ascentage Pharma (AAPG) with $126 million [1] - The majority of other companies raised amounts mostly under $20 million, with nearly 70% of companies financing not exceeding $10 million [1] Group 3 - De-SPAC (Special Purpose Acquisition Company) and OTC transfer models play important supplementary roles, with 8 companies listing through De-SPAC, including Global IBO Group Ltd, which achieved a valuation of $8.3 billion, marking one of the largest transactions of the year [2] - One company, Tianci International Inc (CIIT), successfully transferred from the OTC market to Nasdaq, a path more suitable for companies that have built liquidity and valuation on the OTC market [2] - The outlook for 2026 suggests that with new Nasdaq regulations increasing the net income standard by 200%, the barriers for traditional IPOs will rise, potentially providing greater opportunities for small and medium enterprises in OTC transfers [2]